tonix
pharmaceuticals
host
live
webinar
antibody
cell
immunity
single
vaccine
enough
stop
webinar
moderated
clive
cookson
financial
times
september
panelists
include
representatives
iavi
merck
tonix
pharmaceuticals
new
york
globe
newswire
tonix
pharmaceuticals
holding
nasdaq
tnxp
tonix
company
biopharmaceutical
company
today
announced
host
live
webinar
thursday
september
et
discuss
concept
two
types
immune
responses
antibody
cell
well
provide
overview
challenges
developing
effective
vaccine
participating
panelists
event
swati
gupta
vice
president
head
emerging
infectious
diseases
scientific
strategy
iavi
click
full
bio
vice
president
head
emerging
infectious
diseases
scientific
strategy
iavi
click
full
bio
seth
lederman
ceo
tonix
pharmaceuticals
click
full
bio
ceo
tonix
pharmaceuticals
click
full
bio
gokul
swaminathan
associate
principal
scientist
investigational
biology
merck
research
laboratories
click
full
bio
webinar
held
virtually
include
q
session
moderated
clive
cookson
renowned
science
editor
financial
times
click
register
access
zoom
link
event
details
follows
event
antibody
cell
immunity
single
vaccine
enough
stop
format
virtual
webinar
followed
moderated
q
session
date
thursday
september
time
et
subsequent
archived
recording
webinar
q
session
available
ir
events
tab
investors
section
tonix
website
tonix
pharmaceuticals
holding
tonix
biopharmaceutical
company
focused
discovering
licensing
acquiring
developing
small
molecules
biologics
treat
prevent
human
disease
alleviate
suffering
tonix
portfolio
primarily
composed
central
nervous
system
cns
immunology
product
candidates
immunology
portfolio
includes
vaccines
prevent
infectious
diseases
biologics
address
immunosuppression
cancer
autoimmune
diseases
cns
portfolio
includes
small
molecules
biologics
treat
pain
neurologic
psychiatric
addiction
conditions
tonix
lead
vaccine
candidate
live
replicating
attenuated
vaccine
based
horsepox
viral
vector
platform
protect
primarily
eliciting
cell
response
tonix
expects
data
animal
studies
fourth
quarter
year
live
horsepox
virus
vaccine
percutaneous
administration
development
protect
smallpox
monkeypox
serves
vector
platform
based
tonix
also
developing
live
replicating
vaccine
candidates
prevention
using
bovine
parainfluenza
vector
tonix
lead
cns
candidate
sl
phase
development
management
fibromyalgia
company
expects
results
unblinded
interim
analysis
september
topline
data
fourth
quarter
tonix
also
currently
enrolling
patients
second
phase
study
management
fibromyalgia
using
sl
results
expected
second
half
sl
also
development
agitation
alzheimer
disease
alcohol
use
disorder
aud
agitation
alzheimer
disease
program
phase
ready
fda
fast
track
designation
aud
program
also
phase
ready
tonix
programs
treating
addiction
conditions
also
include
cocaine
esterase
mg
solution
phase
development
treatment
cocaine
intoxication
fda
breakthrough
therapy
designation
cr
tianeptine
oxalate
tablets
another
cns
program
currently
phase
development
daytime
treatment
depression
intranasal
oxytocin
development
treatment
migraine
pain
tonix
preclinical
pipeline
includes
triple
reuptake
inhibitor
new
molecular
entity
developed
treatment
ptsd
monoclonal
antibody
developed
prevent
treat
organ
transplant
rejection
autoimmune
conditions
biologic
developed
treat
gastric
pancreatic
cancers
investigational
new
biologics
approved
indication
sl
cr
investigational
new
drugs
approved
indication
press
release
information
tonix
found
statements
certain
statements
press
release
within
meaning
private
securities
litigation
reform
act
statements
may
identified
use
words
anticipate
believe
forecast
estimate
expect
intend
among
others
statements
based
tonix
current
expectations
actual
results
could
differ
materially
number
factors
could
cause
actual
events
differ
materially
indicated
statements
factors
include
limited
risks
related
failure
obtain
fda
clearances
approvals
noncompliance
fda
regulations
delays
uncertainties
caused
global
pandemic
risks
related
timing
progress
clinical
development
product
candidates
need
additional
financing
uncertainties
patent
protection
litigation
uncertainties
government
third
party
payor
reimbursement
limited
research
development
efforts
dependence
upon
third
parties
substantial
competition
pharmaceutical
development
significant
risks
development
regulatory
approval
commercialization
new
products
tonix
undertake
obligation
update
revise
statement
investors
read
risk
factors
set
forth
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
march
periodic
reports
filed
sec
date
thereof
tonix
statements
expressly
qualified
risk
factors
cautionary
statements
information
set
forth
herein
speaks
date
thereof
contacts
jessica
morris
corporate
tonix
pharmaceuticals
olipriya
das
media
russo
partners
peter
vozzo
investors
westwicke
